Anti-IL-6 and anti-IL-6R, monoclonal antibodies currently approved for treatment of rheumatoid arthritis by inhibiting JAK pathway signaling. In vitro anti-IL-6 antibody treatment of LGLL patients’ PBMCs led to malignant cell apoptosis (12). This evidence concerns the gene IL6 and rheumatoid arthritis.